Epithelial Membrane Protein 2 (EMP2) is emerging as a promising membrane protein target in cancer therapy. Recent studies have explored EMP2-targeting strategies, including siRNA delivery systems, monoclonal antibodies, and ADCs, demonstrating potential in suppressing tumor progression and modulating the tumor immune microenvironment.
DIMA Biotechnology provides in-stock biotin-labeled full-length membrane proteins prepared using Nanodisc technology. Expressed in mammalian cells to preserve native conformation and biological function, these proteins effectively support SPR/BLI binding analysis, antibody discovery, CAR-T positivity assessment, and research on challenging membrane protein targets.
June 2026 Biopharma Deal Wave: Multibillion-Dollar M&A Surges Alongside Licensing Deals for Cutting-Edge Technologies Such as T-Cell Engagers and RNA Editing. Chinese Pharmaceutical Companies Are Expanding Their Global Partnerships from Single-Asset Licensing to Multi-Target Platform Deals, While Oncology Continues to Lead and Attract Strong Global Investor Interest.
The first STEAP1-targeted therapy, Xaluritamig, has delivered promising Phase III clinical results, achieving a PSA50 response rate of 59%. Multiple therapeutic modalities，including bispecific ADCs, CAR-T cells, and trispecific T-cell engagers are advancing rapidly and demonstrating strong potential, ushering in a new era of targeted therapy for prostate cancer.
The approval of the world’s first CAR-T therapy for solid tumors not only marks a new milestone in CAR-T treatment, but also brings CLDN18.2 into the spotlight as a highly attractive target. During CAR-T development, accurately and reliably detecting CAR positivity is an important foundation for evaluating product quality and functional performance.
Classic targets such as EGFR, RET, RAS, ER, and AR continue to evolve, while precision oncology advances from identifying driver mutations toward earlier intervention and more refined patient stratification.
Bispecific antibody development is evolving beyond simply combining two targets, with T-cell engagers, PD-1×VEGF, PD-1×CTLA-4, and 4-1BB-based approaches emerging as key drivers of next-generation immuno-oncology innovation.
Beyond HER2 and TROP2, emerging targets such as CLDN18.2, B7-H3, FOLR1, and HER3 are rapidly gaining momentum, signaling a shift in ADC development from established targets to a highly competitive multi-target landscape.
From April to May 2026, global biopharma dealmaking rebounded, with major pharma focusing on de-risked assets and growing interest in platform technologies such as ADCs, TCEs, and multispecific antibodies. Meanwhile, Chinese biotech accelerated global expansion, oncology shifted toward “platform technology + multi-mechanism combinations,” and AI drug discovery moved closer to real-world industrial adoption.
With updated Phase III clinical data released by Roche in 2025, trontinemab has emerged as a leading example of TfR1-mediated blood–brain barrier delivery, achieving high amyloid clearance with low ARIA-E incidence in Alzheimer’s disease patients. By exploiting TfR1-dependent transcytosis, this bispecific antibody highlights TfR1/CD71 not only as a central regulator of iron metabolism, but also as a highly promising gateway for CNS therapeutic delivery.